<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20201213049697N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2021-09-07</date_registration>
      <primary_sponsor>Esfahan University of Medical Sciences</primary_sponsor>
      <public_title>Comparison of preventive effects of Ketamine ,fentanyl and paracetamol  on Hemodynamic parameters and  acute postoperative pain after deep vitrectomy</public_title>
      <acronym></acronym>
      <scientific_title>Comparison of preventive effects of Ketamine ,fentanyl and paracetamol  on Hemodynamic parameters and  acute postoperative pain after deep vitrectomy</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2020-12-16</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>80</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/52976</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Not used, Assignment: Parallel, Purpose: Prevention, Randomization description: Before starting the project, the sequence of patients in 4 groups is determined using random allocation software And patients are divided into 4 groups receiving ketamine (group K), group receiving fentanyl (group (f), group receiving paracetamol (group p) and control group
 
It(drug) is delivered in covered syringes and has a code. The medicine is prepared by an operating room technician and the doctor is unaware of the contents of the syringe.
Randomization is simple.
It is an individual randomization unit.
Randomization is done by random allocation, Blinding description: Prior to surgery, patients will be told that their pain intensity and hemodynamic parameters will be assessed after surgery,  patients will  be told if they are compared to other groups, and then their consent form will be obtained Becomes
The medicine is prepared by an operating room technician and the doctor is unaware of the contents of the syringe
In order for the study to be bi-blind, two different people will be used so that the anesthesiologist will prescribe the medication And the other person does not know the type of drug used Collects data and analyzes information.
In fact, the drugs are prepared by the anesthesia technician and delivered to the anesthesiologist in sealed and numbered syringes.
The anesthesiologist does not know the type of drug injected into the patient.
Also, data related to the study during and after the operation will be collected and analyzed by someone other than the anesthesiologist and anesthesiology Technician.</study_design>
      <phase>3</phase>
      <hc_freetext>Most cases of vitrectomy are performed due to retinal detachment for any reason, including diabetes, trauma, etc..</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: Ketamine (Group K) 0.5mg / kg will be opened by intravenous infusion within 15 minutes after the volume of the above drugs is increased to 100 cc by sterile normal saline solution .Drug of a special pharmaceutical factory is not consider .The duration of the patient follow-up period after injecting drugs is 24 hours,  which the patient's vital signs, pain intensity, and medications are recorded at specified intervals. Intervention 2: Intervention group: The fentanyl group receiving 2mcg / kg will be infused intravenously within 15 minutes after the volume of the above drugs is increased to 100 cc by sterile normal saline solution. Drug of a special pharmaceutical factory is not consider . The duration of the patient follow-up period after injecting drugs is 24 hours,  which the patient's vital signs, pain intensity, and medications are recorded at specified intervals. Intervention 3: Intervention group: Paracetamol group receiving 10 mg / kg will be infused intravenously within 15 minutes after the volume of the above drugs is increased to 100 cc by sterile normal saline solution. Drug of a special pharmaceutical factory is not consider . The duration of the patient follow-up period after injecting drugs is 24 hours,  which the patient's vital signs, pain intensity, and medications are recorded at specified intervals. Intervention 4: Control group: 100 cc normal saline for 15 minutes intravenously.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
In this study, only data related to the effect of drugs on hemodynamic parameters and acute postoperative pain will be published and potential data information will be published only after the necessary coordination with the executor and ensuring the scientific rank and purpose of the person requesting the information.

When:
One year after the results are published

To whom:
Researchers working in academic and scientific institutions

Conditions:
The data will be provided to the mentioned people for comparative studies as well as systematic studies

Where to obtain:
razani113774@gmail.com ,Mohammad Razani, Isfahan University of Medical Sciences

09381793755 ,Mohammad Razani, Isfahan University of Medical Sciences

How to obtain:
Depending on the type of information requested, the person communicates with the researcher through the channels provided and finally receives his / her answer within one month.

Comments:
</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Darioush Moradi Farsani</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Hezar Jerib St</address>
        <city>Esfahan</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>8174673461</zip>
        <telephone>+98 31 3668 8138</telephone>
        <email>drdmoradi@gmail.com</email>
        <affiliation>Esfahan University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Darioush Moradi Farsani</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Hezar jarib  St</address>
        <city>Esfahan</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>8174673461</zip>
        <telephone>031 3668 81388</telephone>
        <email>drdmoradi@gmail.com</email>
        <affiliation>Esfahan University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>all patient candidate for deep vitrectomy surgery</inclusion_criteria>
      <agemin>40 years</agemin>
      <agemax>80 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>each surgery that long more than 3 or less than 1 hour
pregnancy
addiction to cigarette ,opium and alcohol
Inability to speak
non iranian nationality
more than 100 kg weight
choronic pain that last more than 6 month
uncontroled systemic diseases such as liver or kidney disease
allergy or anaphylaxy to NSAID ,opium and drug that we use in study
psychosis ,obvious anxiety before surgery and History of taking anti-anxiety medication</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code></hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword></hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Placebo</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: Ketamine (Group K) 0.5mg / kg will be opened by intravenous infusion within 15 minutes after the volume of the above drugs is increased to 100 cc by sterile normal saline solution .Drug of a special pharmaceutical factory is not consider .The duration of the patient follow-up period after injecting drugs is 24 hours,  which the patient's vital signs, pain intensity, and medications are recorded at specified intervals.</i_keyword>
      <i_keyword>Intervention group: The fentanyl group receiving 2mcg / kg will be infused intravenously within 15 minutes after the volume of the above drugs is increased to 100 cc by sterile normal saline solution. Drug of a special pharmaceutical factory is not consider . The duration of the patient follow-up period after injecting drugs is 24 hours,  which the patient's vital signs, pain intensity, and medications are recorded at specified intervals.</i_keyword>
      <i_keyword>Intervention group: Paracetamol group receiving 10 mg / kg will be infused intravenously within 15 minutes after the volume of the above drugs is increased to 100 cc by sterile normal saline solution. Drug of a special pharmaceutical factory is not consider . The duration of the patient follow-up period after injecting drugs is 24 hours,  which the patient's vital signs, pain intensity, and medications are recorded at specified intervals.</i_keyword>
      <i_keyword>Control group: 100 cc normal saline for 15 minutes intravenously</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Hemodynamic changes (blood pressure, respiration rate, heart rate, blood oxygen saturation). Timepoint: Before the operation, during the operation (at intervals of 15 minutes, 30 minutes, one hour, two hours), after the operation (at intervals of 15 minutes, 30 minutes, one hour, two hours, 4 hours, 16 hours , 24 hours ). Method of measurement: Mercury sphygmomanometer, clock, pulse oximeter.</prim_outcome>
      <prim_outcome>Acute pain after surgery. Timepoint: Before the operation, during the operation (at intervals of 15 minutes, 30 minutes, one hour, two hours), after the operation (at intervals of 15 minutes, 30 minutes, one hour, two hours, 4 hours, 16 hours , 24 hours ). Method of measurement: Visual Analogue Scale.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Esfahan University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2020-12-03</approval_date>
        <contact_name>Ethics Committee of Isfahan University of Medical Sciences</contact_name>
        <contact_address>esfahan university of medical science, Hezar jarib Ave ,Darvaze shiraz square esfahan Isfehan Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
